INMB

INmune BioF

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

Current thesis

Composite grade F from latest DB weights. Momentum 16.2 / Value 40.6

Posture

Defensive

Lead driver

Value

What changed

Next scheduled catalyst: earnings 2026-11-04.

What can break

Mixed signals. Wait for cleaner trend confirmation.

Momentum

Value

Sentiment

N/A

Setup hits (3d)

0 · Net Neutral

AI TargetsBase - · Bull - · Bear -Analysis date unavailable; returns require an exact persisted reference.

Earnings

2026-11-04

Data freshness

Prices

Unavailable: Price unavailable

Fundamentals

As of 2026-10-27 • Vendor: Data Vendor v1

Scores

As of 2026-10-28 • Model: HYBRID_IC_RP

AI Memo

Unavailable: No memo yet

Investment thesis

As of 2026-10-28

Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-28. Definitions

Supporting evidence

What

Grade F · Defensive

Confidence Medium · Net Neutral

Target $7.00

Why

Momentum16 · Δ7d -

Value41 · Δ7d -0.1

SentimentN/A · Δ7d -

So what

Weak posture (Net Neutral). Prioritize risk control and patience.

Confirming evidence

• Next scheduled catalyst: earnings 2026-11-04.
• Value remains the lead driver in the composite, 7D delta -0.1.

Contradictions & invalidation

• Mixed signals. Wait for cleaner trend confirmation.

Catalyst clock

2026-11-04

Lead driver: Value · See fundamentals

Momentum

15% active weight

Current posture

7d trendTrend unavailable

Trend unavailable

Δ7d

Δ21d

Value

85% active weight

Current posture

7d trendFlat

Δ7d

-0.1

Δ21d

-0.3

Sentiment

N/A

Coverage pending

No current score

7d trendTrend unavailable

Trend unavailable

Δ7d

Δ21d

Why this grade

Composite grade F. Momentum 16.2 / Value 40.6

Fundamentals (TTM)

As of 2026-10-27

Market Cap

$42.19M

Beta

0.73

Shares Out

27.75M

P/E (TTM) · Derived

-0.8

P/S (TTM)

792.24

P/FCF (TTM) · Derived

-2.57

Rev YoY

-100.0%

EPS YoY

-95.5%

Gross Margin

Op Margin

-102752.0%

Net Debt

-$23.72M

Current Ratio

4.04

As of 2026-10-28 • Updated nightlySource: Internal modelMethods & Data